Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Shareholder Meeting (November 2021)
13 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 18, 2021
Slide 1: 2021 AGM Chairman's Address and CEO Presentation
18 November, 2021 For personal use only 2021 AGM Chairman’s Address and CEO Presentation PYC Therapeutics (ASX:PYC) (PYC or the Company) submits the following Chairman’s Address and CEO Presentation to be made at the 2021 Annual General Meeting being held today at The Harry Perkins Institute of Medi
Slide 2: Chairman's Address
For personal use only CHAIRMANS ADDRESS It’s been another year of significant progress for the Company. You will hear later from the CEO, Rohan Hockings, details of the most recent exciting results and the plans for the future. In my view these results mark a major milestone in the development of th
Slide 3: Chairman's Address (continued)
The validation of the drug delivery platform has significance not only for the in-house drugs being developed but also for collaboration with other organisations within the pharmaceutical sector. Discussions will continue to progress with parties who show interest in this technology. Drug developmen
Slide 4: Life-changing science: Annual General Meeting November 2021
For personal use only Life-changing Annual General Meeting science November 2021
Slide 5: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A
Slide 6: CEO presentation
CEO presentation For personal use only There are three main topics for discussion today: 1• Portfolio development strategy – how and why are PYC building out the drug development pipeline? 2• The non-human primate tolerability and safety data - how this creates an opportunity to scale PYC’s RNA tech
Slide 7: Five underpinnings of PYC's portfolio development strategy
There are five clear and simple underpinnings of PYC’s portfolio development strategy For personal use only Discovery Lead selection IND-enabling Clinical Marketed 1 High value markets: Pursue high value target markets representing a 2 With no competition: significant unmet patient Create first in c
Slide 8: Tolerability and safety results in the dose range finding study in non-human primates
The tolerability and safety results in the dose range finding study in non-human primates For personal use only Tolerability findings observed in cynomolgous monkeys 29 days following a single intravitreal injection of VP-001 Dose of VP-001 Total number No findings of adverse tolerability Findings o
Slide 9: The investment proposition in PYC is evolving rapidly
The investment proposition in PYC is evolving rapidly For personal use only 1. There is significant read-through from the RP11 non-clinical safety and tolerability outcomes for PYC’s entire ocular pipeline 2. As PYC approaches first in human studies, the driver of the investment proposition is evolv
Slide 10: Value is created early in programs directed towards monogenic diseases
Value is created early in drug programs directed towards monogenic diseases with high quality non-clinical models For personal use only PYC’s drug development pipeline is anchored around 3 candidates for monogenic diseases The extraordinary clinical success rates for drug development programs with t
Slide 11: PYC is developing a rapidly scalable platform technology
PYC is developing a rapidly scalable platform technology For personal use only PYC’s RNA therapeutic development platform scales rapidly The Company has made a significant investment in discovery work across multiple target tissues and indications in 2020/2021 and expects to see a significant expans
Slide 12: An RNA company positioned for growth
An RNA company positioned for growth For personal use only Scalability Multiple assets Unprecedented success rates A platform technology With multiple programs That are >5x more likely to progressing into the clinic be approved¹ A precision medicine Initial focus on blinding eye PYC’s genetic medici
Slide 13: The outlook for 2022
The outlook for 2022 For personal use only Clinical-stage Growing patient-impact Scaling a platform PYC transitions to a Reaching millions more Scaling a platform clinical-stage company patients with common technology into the diseases precision medicine era 2 clinical trials initiated in Validation
PYC Therapeutics — Shareholder Meeting (November 2021) on 6ix